Literature DB >> 24646486

Conventional dosing of anticancer agents: precisely wrong or just inaccurate?

S Bins1, M J Ratain2, R H J Mathijssen1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24646486     DOI： 10.1038/clpt.2014.12

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

Authors:  Neeraj Gupta; Yuan Zhao; Ai-Min Hui; Dixie-Lee Esseltine; Karthik Venkatakrishnan
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

2.  Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Authors:  A J M Nieuweboer; M Smid; A-J M de Graan; S Elbouazzaoui; P de Bruijn; F A L M Eskens; P Hamberg; J W M Martens; A Sparreboom; R de Wit; R H N van Schaik; R H J Mathijssen
Journal:  Pharmacogenomics J       Date:  2015-09-08       Impact factor: 3.550

3.  Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Authors:  A Janssen; C P M Verkleij; A van der Vlist; R H J Mathijssen; H J Bloemendal; R Ter Heine
Journal:  Br J Cancer       Date:  2017-04-11       Impact factor: 7.640

Review 4.  Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

Authors:  Neeraj Gupta; Michael J Hanley; Paul M Diderichsen; Huyuan Yang; Alice Ke; Zhaoyang Teng; Richard Labotka; Deborah Berg; Chirag Patel; Guohui Liu; Helgi van de Velde; Karthik Venkatakrishnan
Journal:  Clin Pharmacol Ther       Date:  2018-03-23       Impact factor: 6.875

5.  Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

Authors:  Femke M de Man; G D Marijn Veerman; Esther Oomen-de Hoop; Maarten J Deenen; Didier Meulendijks; Caroline M P W Mandigers; Marcel Soesan; Jan H M Schellens; Esther van Meerten; Teun van Gelder; Ron H J Mathijssen
Journal:  Ther Adv Med Oncol       Date:  2019-04-15       Impact factor: 8.168

Review 6.  Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.

Authors:  Mohamad Shebley; Rajeev M Menon; John P Gibbs; Nimita Dave; Su Y Kim; Patrick J Marroum
Journal:  J Clin Pharmacol       Date:  2018-12-18       Impact factor: 3.126

7.  The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients.

Authors:  Leni van Doorn; Marie-Rose B S Crombag; Hánah N Rier; Jeroen L A van Vugt; Charlotte van Kesteren; Sander Bins; Ron H J Mathijssen; Mark-David Levin; Stijn L W Koolen
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-09

8.  Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.

Authors:  Sophia Liva; Min Chen; Amir Mortazavi; Alison Walker; Jiang Wang; Kristin Dittmar; Craig Hofmeister; Christopher C Coss; Mitch A Phelps
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-10-07       Impact factor: 2.441

9.  Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.

Authors:  Anna Dorothea Wagner
Journal:  ESMO Open       Date:  2020-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.